Especially in Japan, the number of DLI has strikingly increased since 2000 [120], and the representative causative drugs are EGFR-TKIs against non-small cell lung cancer (NSCLC), including gefitinib [4] and erlotinib [121], and antirheumatic drugs including leflunomide [122]. Here, EGFR is linked to non-small cell lung carcinoma.